Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development and validation of a framework using multiple sources of real-world data to assess the benefit-risk balance of advanced therapies in inflammatory bowel disease

Project description

Leveraging real-world data to assess inflammatory bowel disease treatment

Evaluating the benefit-risk balance of treatments is essential in medicine but presents challenges, particularly in inflammatory bowel diseases (IBD). Although new therapies are available, their optimal position is unclear due to the absence of head-to-head comparison. Recent emulated trials have highlighted the effectiveness of real-world data in assessing IBD treatments. The ERC-funded FORECAST project aims to validate algorithms that identify patient characteristics and outcomes using nationwide healthcare databases. It will emulate clinical trials comparing advanced therapies in IBD, integrate findings with patient preferences into a clinical decision support system and evaluate this system through a pragmatic randomised controlled trial. The project will also establish post-marketing drug surveillance methods applicable to future IBD therapies and other chronic diseases.

Objective

Assessing the benefit-risk balance of treatment is crucial in medicine to select the most appropriate treatment for patients. This process faces major challenges, how to implement evidence in real time to guide treatment choice and how to summarize efficacy and safety outcomes to patients and clinicians, while incorporating patient preferences. Inflammatory bowel diseases (IBD) affect 3 million residents in Europe. New advanced therapies have been recently approved, but in the absence of head-to-head randomized controlled trials (RCT), data are lacking to position each drug in the therapeutic management. Multiple types of real-world data (RWD) sources are available to assess the effect of treatment, but each type has its proper strengths and limitations. Linking multiple RWD sources can overcome limitations and leverage the strengths of each data source. We recently emulated clinical trials supporting the use of RWD to assess treatment effectiveness and safety in IBD.
Based on the linkage of nationwide healthcare databases, electronic health records, and a prospective cohort of IBD patients, the aims of the current proposal are (i) to validate algorithms identifying IBD characteristics and outcomes in nationwide healthcare databases, (ii) to emulate head-to-head clinical trials comparing advanced therapies in IBD, (iii) to incorporate trials findings and patient preferences in a clinical decision support system for IBD patients and clinicians, whose impact will be assessed by a pragmatic RCT nested in nationwide healthcare databases.
This challenging project will involve multi-disciplinary aspects, from qualitative approach to artificial intelligence, to clarify the position of each treatment in IBD and disseminate findings to patients and clinicians. Besides scientific importance, it will have societal impact by setting the stage for a novel post-marketing drug surveillance framework applicable not only to future IBD treatments but also to other chronic diseases.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

SORBONNE UNIVERSITE
Net EU contribution
€ 681 673,00
Address
21 RUE DE L'ECOLE DE MEDECINE
75006 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 681 673,00

Beneficiaries (2)